Recruiting

Dupilumab

Sponsor:

Sanofi

Code:

NCT07612878

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Cohort 1: Dupilumab

Cohort 2: usual care only

Study Details

Brief summary:

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Study ID

NCT07612878

Start date

Aug 6, 2026

Status verified date

Aug, 2026

Completion date

Nov 30, 2029

Anticipated

Primary completion date

Jun 30, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • COPD patients who are newly referred to start dupilumab treatment
  • Age ≥ 40 years
  • Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit

Exclusion Criteria:

  • Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)
  • Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
  • Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Study Design

Enrollment

350 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1: COPD participants prescribed dupilumab

350 COPD consented participants prescribed dupilumab with prospective data collection

Cohort 2: Control COPD participants not prescribed dupilumab

700 COPD control participants from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. These participants will not be consented with retrospective data collection.

Interventions

Cohort 1: Dupilumab

medicine already approved by the FDA

Cohort 2: usual care only

Usual care that patients receive

Primary outcome measure

  • Participant Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Participant Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Participant Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patients Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patients Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]
  • Patient Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]

Central Contacts and Locations

Central contacts

Trial Transparency Trial Transparency

800-633-1610 option 6Contact-us@sanofi.com

Locations

IU Health Pulmonology & Critical Care Medicine

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Kim McPeak

(317) 962-5820kmcpeak@IUHealth.org

Principal Investigator:

Marc Rovner, MD, MMM, CPE, FACP, FCCP

University of Kansas

Recruiting

Lawrence, Kansas, United States, 66045

Contacts

Laurin Brown

913 588 2077lbrown37@kumc.edu

Principal Investigator:

Matthew Sharpe, MD

Duke

Recruiting

Durham, North Carolina, United States, 27705

Contacts

Jessica Shier

919-620-7300jessica.shier@duke.edu

Principal Investigator:

Matt McCravy, MD

Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Michael Woods Study Coordinator

614 293 4925michael.woods@osumc.edu

Principal Investigator:

Phil Diaz, MD

The Respire Institute

Recruiting

Houston, Texas, United States, 77094

Contacts

Janeth Rodriguez

713 464 0899jrodriguez@mpsds.com

Principal Investigator:

Murtuza Ahmed, MD

Activian Clinical Research

Recruiting

Kingwood, Texas, United States, 77339

Contacts

Katie Rice

832 225 4800krice@activian.com

Principal Investigator:

Amanbir Sohal, MD

The Lung & Sleep Institute of North Texas

Recruiting

North Richland Hills, Texas, United States, 76180

Contacts

Neha Nair

817-284-9225neha@lungsleeptexas.com

Principal Investigator:

Tamer Hudali, MD MPH

More Information

Sponsor

Sanofi

Last update posted

Oct 15, 2026

Last verified

Aug, 2026

Keywords

  • COPD
  • Dupilumab
  • Dupixent
  • Chronic Obstructive Pulmonary Disease
  • Exacerbation
  • Home Spirometry

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-16. This information was provided to ClinicalTrials.gov by Sanofi on 2026-10-15. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.